RD

RadNet, Inc.

RDNTHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.04B
+11.5% YoY
Net Income
-$18.7M
-767.8% YoY
EBITDA
$313.8M
-2.9% YoY
Free Cash Flow
$190.5M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 11 RSI OverboughtRSI 76.8, above 70, stock may be overbought
Jul 10 RSI OverboughtRSI 78.9, above 70, stock may be overbought
About RadNet, Inc.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. At a $4.89B market cap, RadNet, Inc. ranks as a mid-cap company within healthcare. The company operates in two segments, Imaging Centers and Digital Health.

Key stats
Market Cap$4.89B
Fwd P/E65.93
EPS$-0.17
Beta1.36
52W Change+8.2%
ROE1.8%
Analysis

RadNet, Inc. carries $1.93B in total debt against $455.3M in cash reserves — debt is roughly 4.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $190.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 1.8% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.43B (2022) to $2.04B (2025), reflecting a 43% increase over the period.

As with any equity investment, RDNT carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RDNT.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms